EARS
$2.84
Auris Medical
EARS
Earnings Whisper ®
N/A
1st Quarter March 2019
Consensus:  $0.00
Revenue:  N/A
Thursday
Jun 27
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EARS reports earnings?
Beat
Meet
Miss

Where is EARS's stock price going from here?
Up
Flat
Down
Stock chart of EARS
Analysts
Summary of analysts' recommendations for EARS
Score
Grade
Pivots
Resistance
$3.23
$3.14
$2.99

$2.90

Support
$2.75
$2.66
$2.51
Tweet
Growth
Description
Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalMylanCelgeneInterCeptZoetisEndo International plcJohnson & JohnsonBristol-Myers Squibb